Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Randomized Trial of Pegylated Interferon Alfa-2a Versus Hydroxyurea in Polycythemia Vera (PV) and Essential Thrombocythemia (ET)

This study is ongoing, but not recruiting participants.
Sponsor:
Collaborators:
Myeloproliferative Disorders-Research Consortium
National Cancer Institute (NCI)
Roche Pharma AG
Information provided by (Responsible Party):
Ronald Hoffman, Icahn School of Medicine at Mount Sinai
ClinicalTrials.gov Identifier:
NCT01259856
First received: December 7, 2010
Last updated: January 10, 2017
Last verified: January 2017
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is ongoing, but not recruiting participants.
  Estimated Study Completion Date: June 2017
  Estimated Primary Completion Date: June 2017 (Final data collection date for primary outcome measure)